74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Krystal Biotech Inc
Closed
SectorHealthcare
167.83 1.64
Overview
Share price change
24h
Min
161.96
Max
169.21
Income | 18M 45M |
|---|---|
Sales | 7.3M 91M |
P/E Sector Avg | 53.97 57.333 |
EPS | 1.53 |
Profit margin | 49.901 |
Employees | 275 |
EBITDA | 12M 43M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +31.57% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | -203M 4.9B |
|---|---|
Previous open | 166.19 |
Previous close | 167.83 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Krystal Biotech Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Krystal Biotech Inc Forecast
Price Target
By TipRanks
31.57% upside
12 Months Forecast
Average 218.14 USD 31.57%
High 245 USD
Low 200 USD
Based on 8 Wall Street analysts offering 12 month price targets forKrystal Biotech Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
